It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!

Mark Lappe Biography and Net Worth

Founder of Inhibrx

Mr. Lappe co-founded Inhibrx in 2010 and has served as Chief Executive Officer since our inception. He also serves as the Chairman of our board of directors. Mr. Lappe has extensive expertise in the biotechnology industry with over 30 years of experience in executive management, investment management, and executive recruiting, having built the executive teams of over 40 start-up biotechnology and medical device companies. Prior to founding Inhibrx, Mr. Lappe was the founder and Managing Partner of Efficacy Biotech Fund, a fund focused on strategic investment in public biotechnology companies.

How old is Mark Paul Lappe?: Mr. Lappe is currently 56 years old. There are 2 older executives and no younger executives at Inhibrx. Learn More on Mark Paul Lappe's age.
How do I contact Mark Paul Lappe?: The corporate mailing address for Mr. Lappe and other Inhibrx executives is 11025 N. TORREY PINES ROAD SUITE 200, LA JOLLA CA, 92037. Inhibrx can also be reached via phone at 858-795-4220 and via email at [email protected]. Learn More on Mark Paul Lappe's contact information.
Has Mark Paul Lappe been buying or selling shares of Inhibrx?: Mark Paul Lappe has not been actively trading shares of Inhibrx in the last ninety days. Learn More on Mark Paul Lappe's trading history.
Who are Inhibrx's active insiders?: Inhibrx's insider roster includes Brendan Eckelman (Insider), Jeffrey Jensen (EVP & Chief Clinical Devel. Officer), and Mark Lappe (Founder). Learn More on Inhibrx's active insiders.
Are insiders buying or selling shares of Inhibrx?: During the last twelve months, Inhibrx insiders bought shares 1 times. They purchased a total of 511,627 shares worth more than $9,899,982.45. The most recent insider tranaction occured on August, 28th when Major Shareholder Global Investors Lp Viking bought 511,627 shares worth more than $9,899,982.45. Insiders at Inhibrx own 25.8% of the company. Learn More about insider trades at Inhibrx.
Information on this page was last updated on 8/28/2023.

Mark Paul Lappe Insider Trading History at Inhibrx

Mark Paul Lappe Buying and Selling Activity at Inhibrx

Inhibrx Company Overview

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Today's Range

Now: $34.38

$34.07

$34.45

50 Day Range

MA: $35.66

$34.10

$39.56

2 Week Range

Now: $34.38

$14.31

$39.79

Volume

218,293 shs

Average Volume

679,345 shs

Market Capitalization

$1.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.91

Will this $2 AI stock double overnight?

From Behind the Markets | Ad